Efficacy and safety of certolizumab pegol in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor
Phase of Trial: Phase IV
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 01 Aug 2017 Planned End Date changed from 31 Mar 2017 to 31 Mar 2020.
- 01 Aug 2017 Status changed from not yet recruiting to recruiting.
- 15 Dec 2015 New trial record